Chugai's Xeloda Obtains Additional Indications, Applies Tarceva For Pancreatic Cancer
This article was originally published in PharmAsia News
Executive Summary
The largest oncology drug maker in Japan, Roche's Japanese unit Chugai Pharmaceutical, obtained approvals for additional indications for anti-cancer drug Xeloda (capecitabine) and additional dosages for Avastin (bevacizumab). The company also submitted an application for an additional indication of pancreatic cancer for Tarceva (erlotinib), currently approved for non-small cell lung cancer in Japan